429 related articles for article (PubMed ID: 26150437)
21. Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure.
de Antonio M; Lupon J; Galan A; Vila J; Urrutia A; Bayes-Genis A
Am Heart J; 2012 May; 163(5):821-8. PubMed ID: 22607860
[TBL] [Abstract][Full Text] [Related]
22. Usefulness of B-type Natriuretic Peptides to Predict Cardiovascular Events in Women (from the Women's Health Study).
Everett BM; Ridker PM; Cook NR; Pradhan AD
Am J Cardiol; 2015 Aug; 116(4):532-7. PubMed ID: 26081066
[TBL] [Abstract][Full Text] [Related]
23. Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk--the atherosclerosis risk in communities study.
Nambi V; Liu X; Chambless LE; de Lemos JA; Virani SS; Agarwal S; Boerwinkle E; Hoogeveen RC; Aguilar D; Astor BC; Srinivas PR; Deswal A; Mosley TH; Coresh J; Folsom AR; Heiss G; Ballantyne CM
Clin Chem; 2013 Dec; 59(12):1802-10. PubMed ID: 24036936
[TBL] [Abstract][Full Text] [Related]
24. Prediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein, and renin in subjects with cerebrovascular disease.
Campbell DJ; Woodward M; Chalmers JP; Colman SA; Jenkins AJ; Kemp BE; Neal BC; Patel A; MacMahon SW
Circulation; 2005 Jul; 112(1):110-6. PubMed ID: 15983245
[TBL] [Abstract][Full Text] [Related]
25. Perindopril-based blood pressure-lowering therapy reduces amino-terminal-pro-B-type natriuretic peptide in individuals with cerebrovascular disease.
Campbell DJ; Woodward M; Chalmers JP; Colman SA; Jenkins AJ; Kemp BE; Neal BC; Patel A; MacMahon SW
J Hypertens; 2007 Mar; 25(3):699-705. PubMed ID: 17278987
[TBL] [Abstract][Full Text] [Related]
26. Multiple marker approach to risk stratification in patients with stable coronary artery disease.
Schnabel RB; Schulz A; Messow CM; Lubos E; Wild PS; Zeller T; Sinning CR; Rupprecht HJ; Bickel C; Peetz D; Cambien F; Kempf T; Wollert KC; Benjamin EJ; Lackner KJ; Münzel TF; Tiret L; Vasan RS; Blankenberg S
Eur Heart J; 2010 Dec; 31(24):3024-31. PubMed ID: 20852293
[TBL] [Abstract][Full Text] [Related]
27. Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study.
Blankenberg S; McQueen MJ; Smieja M; Pogue J; Balion C; Lonn E; Rupprecht HJ; Bickel C; Tiret L; Cambien F; Gerstein H; Münzel T; Yusuf S;
Circulation; 2006 Jul; 114(3):201-8. PubMed ID: 16831981
[TBL] [Abstract][Full Text] [Related]
28. Multimarker approach with cystatin C, N-terminal pro-brain natriuretic peptide, C-reactive protein and red blood cell distribution width in risk stratification of patients with acute coronary syndromes.
Vieira C; Nabais S; Ramos V; Braga C; Gaspar A; Azevedo P; Álvares Pereira M; Salomé N; Correia A
Rev Port Cardiol; 2014 Mar; 33(3):127-36. PubMed ID: 24674467
[TBL] [Abstract][Full Text] [Related]
29. A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLlaboration on Acute decompeNsated Heart Failure: ELAN-HF Score.
Salah K; Kok WE; Eurlings LW; Bettencourt P; Pimenta JM; Metra M; Bayes-Genis A; Verdiani V; Bettari L; Lazzarini V; Damman P; Tijssen JG; Pinto YM
Heart; 2014 Jan; 100(2):115-25. PubMed ID: 24179162
[TBL] [Abstract][Full Text] [Related]
30. Multimodality Strategy for Cardiovascular Risk Assessment: Performance in 2 Population-Based Cohorts.
de Lemos JA; Ayers CR; Levine BD; deFilippi CR; Wang TJ; Hundley WG; Berry JD; Seliger SL; McGuire DK; Ouyang P; Drazner MH; Budoff M; Greenland P; Ballantyne CM; Khera A
Circulation; 2017 May; 135(22):2119-2132. PubMed ID: 28360032
[TBL] [Abstract][Full Text] [Related]
31. Clinical utility of N-terminal pro-B-type natriuretic peptide for risk stratification of patients with acute decompensated heart failure. Derivation and validation of the ADHF/NT-proBNP risk score.
Scrutinio D; Ammirati E; Guida P; Passantino A; Raimondo R; Guida V; Sarzi Braga S; Pedretti RF; Lagioia R; Frigerio M; Catanzaro R; Oliva F
Int J Cardiol; 2013 Oct; 168(3):2120-6. PubMed ID: 23395457
[TBL] [Abstract][Full Text] [Related]
32. Addition of Novel Biomarkers for Predicting All-Cause and Cardiovascular Mortality in Prevalent Hemodialysis Patients.
Yamashita K; Mizuiri S; Nishizawa Y; Shigemoto K; Doi S; Masaki T
Ther Apher Dial; 2018 Feb; 22(1):31-39. PubMed ID: 28971590
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial.
Omland T; Sabatine MS; Jablonski KA; Rice MM; Hsia J; Wergeland R; Landaas S; Rouleau JL; Domanski MJ; Hall C; Pfeffer MA; Braunwald E;
J Am Coll Cardiol; 2007 Jul; 50(3):205-14. PubMed ID: 17631211
[TBL] [Abstract][Full Text] [Related]
34. Amino-terminal-pro-B-type natriuretic peptide levels and low diastolic blood pressure: potential relevance to the diastolic J-curve.
Campbell DJ; McGrady M; Prior DL; Coller JM; Boffa U; Shiel L; Liew D; Wolfe R; Stewart S; Reid CM; Krum H
J Hypertens; 2014 Nov; 32(11):2158-65; discussion 2165. PubMed ID: 25275245
[TBL] [Abstract][Full Text] [Related]
35. Circulating biomarkers for long-term cardiovascular risk stratification in apparently healthy individuals from the MONICA 10 cohort.
Frary CE; Blicher MK; Olesen TB; Stidsen JV; Greve SV; Vishram-Nielsen JK; Rasmussen SL; Olsen MH; Pareek M
Eur J Prev Cardiol; 2020 Apr; 27(6):570-578. PubMed ID: 31718257
[TBL] [Abstract][Full Text] [Related]
36. High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR trial.
Harutyunyan MJ; Mathiasen AB; Winkel P; Gøtze JP; Hansen JF; Hildebrandt P; Jensen GB; Hilden J; Jespersen CM; Kjøller E; Kolmos HJ; Gluud C; Kastrup J;
Scand J Clin Lab Invest; 2011 Feb; 71(1):52-62. PubMed ID: 21108561
[TBL] [Abstract][Full Text] [Related]
37. Age-Related Differences in the Contribution of Systolic Blood Pressure and Biomarkers to Cardiovascular Disease Risk Prediction: The Atherosclerosis Risk in Communities (ARIC) Study.
Al Rifai M; Taffet GE; Matsushita K; Virani SS; De Lemos J; Khera A; Berry J; Ndumele C; Aguilar D; Sun C; Hoogeveen RC; Selvin E; Ballantyne CM; Nambi V
Am J Cardiol; 2023 Oct; 204():295-301. PubMed ID: 37567021
[TBL] [Abstract][Full Text] [Related]
38. N-Terminal Fragment of Pro B-type Natriuretic Peptide as a Marker of Contrast-Induced Nephropathy After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction.
Goussot S; Mousson C; Guenancia C; Stamboul K; Brunel P; Brunet D; Touzery C; Cottin Y; Zeller M
Am J Cardiol; 2015 Sep; 116(6):865-71. PubMed ID: 26183794
[TBL] [Abstract][Full Text] [Related]
39. Association of cardiac biomarkers with long-term cardiovascular events in a community cohort.
Churchill RA; Gochanour BR; Scott CG; Vasile VC; Rodeheffer RJ; Meeusen JW; Jaffe AS
Biomarkers; 2024 Jun; 29(4):161-170. PubMed ID: 38666319
[TBL] [Abstract][Full Text] [Related]
40. Combined use of high-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide for risk stratification of vascular surgery patients.
Scrutinio D; Guido G; Guida P; Passantino A; Angiletta D; Santoro D; Marinazzo D; Regina G
Ann Vasc Surg; 2014 Aug; 28(6):1522-9. PubMed ID: 24524956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
